Supplementary information

Supplementary Figure 2

Allele-specific PCR to detect the wild-type (p53 WT) and mutant allele (p53 Neo) in tumours derived from E-myc/p53^+/- HSCs.

Supplementary Figure 2 - Download PDF file (51.5KB)

Supplementary Figure 3

Kaplan-Meier plots detailing the survival time following treatment with CTX (a) and DXR (b).

Supplementary Figure 3 - Download PDF file (7.52KB)

Supplementary Figure 4

Overall survival of mice treated with rapamycin alone or in combination with conventional chemotherapy.

Supplementary Figure 4 - Download PDF file (11.9KB)

Supplementary Figure 5

Kaplan-Meier analysis of tumour free survival in Akt tumour bearing mice (a) following treatment with CTX (n = 16, red), RAP (n = 12, blue), or CTX+RAP (C+R, n = 8) and in Bcl-2 tumour bearing mice (b) treated with CTX (n = 6, red), RAP (n = 6, blue) and CTX+RAP (C+R, n=4, green).

Supplementary Figure 5 - Download PDF file (8.92KB)

Supplementary Figure 6

Rapamycin reverses chemoresistance in matched Akt-expressing lymphomas.

Supplementary Figure 6 - Download PDF file (4.91KB)

Supplementary Figure 7

Quantification of eIF4E expression in lysates derived from Bcl-2 (n=3), Akt (n=5) and eIF4E (n=5) tumours.

Supplementary Figure 7 - Download PDF file (48.4KB)

Supplementary Table 1

Immunophenotype of Emmyc tumours expressing Akt, Bcl-2 or eIF4E. PDF, 168kB

Supplementary Table 1 - Download PDF file (164KB)

Supplementary Figure Legends

Supplementary Figure Legends - Download rtf (8.91KB)